Sprint Bioscience AB (SPRINT) - Cash Flow Conversion Efficiency

Latest as of September 2025: -2.290x

Based on the latest financial reports, Sprint Bioscience AB (SPRINT) has a cash flow conversion efficiency ratio of -2.290x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-13.89 Million ≈ $-1.49 Million USD) by net assets (Skr6.06 Million ≈ $652.58K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Sprint Bioscience AB - Cash Flow Conversion Efficiency Trend (2012–2024)

This chart illustrates how Sprint Bioscience AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Sprint Bioscience AB debt and liabilities for a breakdown of total debt and financial obligations.

Sprint Bioscience AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sprint Bioscience AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Cayman Tung Ling Co Ltd TWO:2924	-0.055x
Golden Heaven Group Holdings Ltd. Ordinary Shares NASDAQ:GDHG	0.020x
Maniker KO:027740	0.165x
Touch Ventures Ltd AU:TVL	0.006x
Centric Holdings S.A AT:CENTR	0.008x
Fortune Indonesia Tbk JK:FORU	-0.061x
Anli International Co Ltd TWO:5223	-0.017x
MDX Public Company Limited BK:MDX	0.004x

Annual Cash Flow Conversion Efficiency for Sprint Bioscience AB (2012–2024)

The table below shows the annual cash flow conversion efficiency of Sprint Bioscience AB from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Sprint Bioscience AB worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr9.27 Million ≈ $997.82K	Skr-23.36 Million ≈ $-2.51 Million	-2.519x	-405.90%
2023-12-31	Skr27.77 Million ≈ $2.99 Million	Skr22.87 Million ≈ $2.46 Million	0.823x	+139.31%
2022-12-31	Skr28.19 Million ≈ $3.03 Million	Skr-59.05 Million ≈ $-6.36 Million	-2.095x	-267.93%
2021-12-31	Skr70.45 Million ≈ $7.58 Million	Skr-40.12 Million ≈ $-4.32 Million	-0.569x	+83.84%
2020-12-31	Skr9.14 Million ≈ $984.04K	Skr-32.22 Million ≈ $-3.47 Million	-3.524x	-38.64%
2019-12-31	Skr11.02 Million ≈ $1.19 Million	Skr-28.00 Million ≈ $-3.01 Million	-2.542x	-396.07%
2018-12-31	Skr37.24 Million ≈ $4.01 Million	Skr-19.08 Million ≈ $-2.05 Million	-0.512x	+37.56%
2017-12-31	Skr28.09 Million ≈ $3.02 Million	Skr-23.05 Million ≈ $-2.48 Million	-0.821x	-394.71%
2016-12-31	Skr28.49 Million ≈ $3.07 Million	Skr7.93 Million ≈ $853.92K	0.278x	+61.03%
2015-12-31	Skr4.82 Million ≈ $518.74K	Skr833.54K ≈ $89.70K	0.173x	+132.66%
2014-12-31	Skr20.32 Million ≈ $2.19 Million	Skr-10.76 Million ≈ $-1.16 Million	-0.529x	+50.07%
2013-12-31	Skr3.36 Million ≈ $361.91K	Skr-3.57 Million ≈ $-383.76K	-1.060x	+49.25%
2012-12-31	Skr1.10 Million ≈ $118.06K	Skr-2.29 Million ≈ $-246.66K	-2.089x	--

About Sprint Bioscience AB

ST:SPRINT Sweden Biotechnology

Market Cap

$35.31 Million

Skr328.15 Million SEK

Market Cap Rank

#23150 Global

#441 in Sweden

Share Price

Skr3.11

Change (1 day)

-3.42%

52-Week Range

Skr0.41 - Skr4.04

All Time High

Skr47.75